Anti-tumor activity of paclitaxel through dual-targeting lipoprotein-mimicking nanocarrier

Journal of Drug Targeting

Volumn 23, Issue 4, 2015, Pages 311-322

  Chen, Conghui ^a   Hu, Haiyang ^a   Qiao, Mingxi ^a   Zhao, Xiuli ^a   Wang, Yinjie ^a   Chen, Kang ^a   Chen, Dawei ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Anti tumor efficacy; Bovine serum albumin; Dual targeting; Folic acid; Paclitaxel

Indexed keywords

BOVINE SERUM ALBUMIN; COUMARIN DERIVATIVE; FOLIC ACID; LIPOPROTEIN; NANOCARRIER; OCTADECYLAMINE; OSTEONECTIN; PACLITAXEL; ANTINEOPLASTIC AGENT; NANOPARTICLE; SIALOGLYCOPROTEIN; SIALOGLYCOPROTEIN GP60;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TUMOR LEVEL; FEMALE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMISTRY; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; METABOLISM; NUDE MOUSE; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; FOLIC ACID; HEP G2 CELLS; HUMANS; LIPOPROTEINS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; PACLITAXEL; SERUM ALBUMIN, BOVINE; SIALOGLYCOPROTEINS;

EID: 84927915711     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.994182     Document Type: Article

References (34)

1. Lichtman SM, Hurria A, Cirrincione CT, et al. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 2012; 23:632-8.
2. Michaud L, Valero V, Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 2000;23:401-28.
3. Lee J, Lee SC, Acharya G, et al. Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharm Res 2003;20:1022-30.
4. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132:171-83.
5. Li FQ, Su H, Wang J, et al. Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for liver targeting. Int J Pharm 2008;349:274-82.
6. Ogawara K, Furumoto K, Nagayama S, et al. Pre-coating with serum albumin reduces receptor-mediated hepatic disposition of polystyrene nanosphere: implications for rational design of nanoparticles. J Control Release 2004;100:451-5.
7. Furumoto K, Yokoe J, Ogawara K, et al. Effect of coupling of albumin onto surface of PEG liposome on its in vivo disposition. Int J Pharm 2007;329:110-16.
8. Yokoe J, Sakuragi S, Yamamoto K, et al. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. Int J Pharm 2008;353:28-34.
9. Sakai N, Baba M, Nagasima Y, et al. SPARC expression in primary human renal cell carcinoma: upregulation of SPARC in sarcoma-toid renal carcinoma. Hum Pathol 2001;32:1064-70.
10. Park K. Albumin: a versatile carrier for drug delivery. J Control Release 2012;157:3.
11. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008;60: 876-85.
12. Elsadek B, Kratz F. Impact of albumin on drug delivery-new applications on the horizon. J Control Release 2012;157:4-28.
13. Fu Q, Sun J, Zhang W, et al. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat Anticancer Drug Discov 2009;4:262-72.
14. Sabharanjak S, Mayor S. Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev 2004;56:1099-109.
15. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004;56:1127-41.
16. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000;41:147-62.
17. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-401.
18. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 2002;54: 675-93.
19. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994;73:2432-43.
20. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004;56:1067-84.
21. Antony AC. The biological chemistry of folate receptors. Blood 1992;79:2807-20.
22. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 2005;94: 2135-46.
23. Liu Y, Sun J, Cao W, et al. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm 2011;421:160-9.
24. Du C, Deng D, Shan L, et al. A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery. Biomaterials 2013;34:3087-97.
25. Yoshizawa T, Hattori Y, Hakoshima M, et al. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur J Pharm Biopharm 2008;70:718-25.
26. Gao W, Xiang B, Meng TT, et al. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. Biomaterials 2013;34: 4137-49.
27. Xu Q, Liu Y, Su S, et al. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. Biomaterials 2012;33: 1627-39.
28. Saul JM, Annapragada AV, Bellamkonda RV. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 2006;114:277-87.
29. Shan L, Cui S, Du C, et al. A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy. Biomaterials 2012;33:146-62.
30. Habeeb AFSA. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem 1966;14:328-36.
31. Xu Y, Jin X, Ping Q, et al. A novel lipoprotein-mimic nanocarrier composed of the modified protein and lipid for tumor cell targeting delivery. J Control Release 2010;146:299-308.
32. Luo LM, Huang Y, Zhao BX, et al. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. Biomaterials 2013;34:1102-14.
33. Zeng N, Hu Q, Liu Z, et al. Preparation and characterization of paclitaxel-loaded DSPE-PEG-liquid crystalline nanoparticles (LCNPs) for improved bioavailability. Int J Pharm 2012;424:58-66.
34. Zhao BX, Zhao Y, Huang Y, et al. The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel. Biomaterials 2012;33:2508-20.